This has been a big week for healthcare and biotech.
/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
Posted by Karen Goldfarb
January 13, 2012 at 11:20 AM
This has been a big week for healthcare and biotech.
Topics: Crystal Research Associates, NVIV, GenSpera, OneMedForum, MedPro, biotech, Advaxis, Peregrine, Neuralstem, Leslie Ziegler, Gunnar Weikert, PPHM, General Cannabis, SearchCore
Posted by Colleen Koski
November 10, 2011 at 10:37 AM
On November 1, 2010, the Pharmaceutical Research and Manufacturers of America (PhRMA) issued a press release discussing new treatments in development for Alzheimer’s disease. Alzheimer’s is a progressive, degenerative brain disease that causes memory loss, personality changes, dementia, and ultimately death. While the greatest risk factor for Alzheimer’s is age—as the majority of patients diagnosed with Alzheimer’s are 65 or older—the disease is not a result of aging. Rather, researchers believe that a combination of genetic, lifestyle, and environmental factors trigger the onset of Alzheimer’s.
Topics: Newsworthy Events, Neuralstem
Posted by Laura Swartz
October 19, 2010 at 10:44 AM
Neuralstem, Inc. (CUR-NYSE Amex) announced on Monday of this week that it would begin enrolling the next group of patients into its ongoing Phase I ALS clinical trial. This trial seeks to demonstrate the safety of surgically injecting stem cells into the spinal cords of patients who are diagnosed with amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease. To date, six non-ambulatory individuals have received stem cell injections in the lumbar spinal cord, and the trial’s Safety Monitoring Board has unanimously approved enrolling the next group of patients. The trial’s next patients will be ambulatory, which represent earlier stages of the disease than have been tested thus far. Ultimately, 18 ALS patients are expected to be enrolled in the Phase I trial, which is underway at Emory University in Atlanta, Georgia.
Topics: Newsworthy Events, Neuralstem
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.
CONTACT INFORMATION
Phone: (212) 851-6685
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS